Background: Reports regarding the relationship between the length and diameter of implanted drug-eluting stents and clinical and angiographic outcomes in dialysis patients are limited. Aim: We investigated the efficiency of drug-eluting stents for coronary artery disease in patients on dialysis from the viewpoint of stent sizing. Methods: Sirolimus-eluting stents were implanted in 88 lesions and bare metal stents were implanted in 43 lesions. We compared stenting strategy, major adverse cardiac events, and angiographic results between sirolimus-eluting stent and bare metal stent groups. Results: Stent diameter was smaller and stent length was longer in the sirolimus-eluting stent group than in the bare metal stent group in our routine pract...
BACKGROUND Drug-eluting stents (DES) showed improved efficacy and safety compared with bare-metal...
Context Percutaneous coronary revascularization of small vessels is associated with a high restenosi...
BACKGROUND: Most drug-eluting stent (DES) trials have excluded patients with chronic kidney disease ...
ObjectivesThis study sought to investigate the influence of vessel size on the outcomes of patients ...
BACKGROUND:Drug-eluting stents (DES) are more effective in reducing restenosis than bare-metal stent...
Background: Restenosis rates are low in large coronary vessels = 3.5 mm after bare-metal stent (BMS)...
Drug-eluting stents (DESs) are superior to bare metal stents (BMSs) in decreasing restenosis rates a...
Aim: This study sought to compare short- and long-term outcomes of drug-eluting stents (DESs) versus...
Background: Drug-eluting stents (DES) showed improved efficacy and safety compared with bare-metal s...
BACKGROUND: Percutaneous coronary intervention with bare metal stents (BMS) in patients with chronic...
To investigate the efficacy and long-term clinical benefits of DES for dialysis patients.It is uncle...
AIMS: To prospectively evaluate the influence of stent length on 6 month clinical and angiographic o...
BackgroundAlthough drug-eluting stents (DES) have been shown to dramatically reduce restenosis and i...
BACKGROUND - : Percutaneous coronary interventions in patients with chronic kidney disease have show...
BACKGROUND: Restenosis remains the major limitation of coronary catheter-based intervention. In smal...
BACKGROUND Drug-eluting stents (DES) showed improved efficacy and safety compared with bare-metal...
Context Percutaneous coronary revascularization of small vessels is associated with a high restenosi...
BACKGROUND: Most drug-eluting stent (DES) trials have excluded patients with chronic kidney disease ...
ObjectivesThis study sought to investigate the influence of vessel size on the outcomes of patients ...
BACKGROUND:Drug-eluting stents (DES) are more effective in reducing restenosis than bare-metal stent...
Background: Restenosis rates are low in large coronary vessels = 3.5 mm after bare-metal stent (BMS)...
Drug-eluting stents (DESs) are superior to bare metal stents (BMSs) in decreasing restenosis rates a...
Aim: This study sought to compare short- and long-term outcomes of drug-eluting stents (DESs) versus...
Background: Drug-eluting stents (DES) showed improved efficacy and safety compared with bare-metal s...
BACKGROUND: Percutaneous coronary intervention with bare metal stents (BMS) in patients with chronic...
To investigate the efficacy and long-term clinical benefits of DES for dialysis patients.It is uncle...
AIMS: To prospectively evaluate the influence of stent length on 6 month clinical and angiographic o...
BackgroundAlthough drug-eluting stents (DES) have been shown to dramatically reduce restenosis and i...
BACKGROUND - : Percutaneous coronary interventions in patients with chronic kidney disease have show...
BACKGROUND: Restenosis remains the major limitation of coronary catheter-based intervention. In smal...
BACKGROUND Drug-eluting stents (DES) showed improved efficacy and safety compared with bare-metal...
Context Percutaneous coronary revascularization of small vessels is associated with a high restenosi...
BACKGROUND: Most drug-eluting stent (DES) trials have excluded patients with chronic kidney disease ...